NCT02646319 - Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

September 5, 2017

Study Completion Date

April 24, 2018

Conditions

Advanced Malignant NeoplasmCervical Squamous Cell CarcinomaEndometrial CarcinomaMalignant Uterine NeoplasmRecurrent Bladder CarcinomaRecurrent Breast CarcinomaRecurrent Cervical CarcinomaRecurrent Head and Neck CarcinomaRecurrent Malignant NeoplasmRecurrent Ovarian CarcinomaRecurrent Prostate CarcinomaRecurrent Renal Cell CarcinomaSolid NeoplasmStage III Bladder CancerStage III Prostate CancerStage III Renal Cell CancerStage IIIA Breast CancerStage IIIA Cervical CancerStage IIIA Ovarian CancerStage IIIB Breast CancerStage IIIB Cervical CancerStage IIIB Ovarian CancerStage IIIC Breast CancerStage IIIC Ovarian CancerStage IV Breast CancerStage IV Ovarian CancerStage IV Prostate CancerStage IV Renal Cell CancerStage IVA Bladder CancerStage IVA Cervical CancerStage IVB Bladder CancerStage IVB Cervical Cancer

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Nanoparticle Albumin-Bound Rapamycin

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (2)

55905

Mayo Clinic, Rochester

85259

Mayo Clinic in Arizona, Scottsdale